Search
The Australian and New Zealand Paediatric Infectious Diseases (ANZPID) Group of the Australasian Society for Infectious Diseases (ASID) calls for urgent consideration of the needs and voices of children in response to the COVID-19 pandemic, and in planning for future pandemics.
Management and outcomes of children hospitalised with acute SARS-CoV-2 infection may differ throughout the pandemic or with admission type (clinical COVID-19, incidental COVID-19 or nosocomial infection).
Our interdisciplinary team initiated a project to inform the COVID-19 vaccination programme. We developed a novel research co-creation approach to share emerging findings with government.
PICOBOO is a randomised, adaptive trial evaluating the immunogenicity and reactogenicity of licensed COVID-19 booster vaccines in immunocompetent individuals >12 years old. Here, we present data for seven different vaccines among three pre-specified participant strata defined by age and primary vaccine schedule.
Optimising our national Covid-19 vaccine program could be one step closer thanks to new research now underway at The Kids Research Institute Australia investigating the most effective, long-term strategies for booster vaccinations.
Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.
In an Australian-first study, researchers at The Kids Research Institute Australia are investigating the effects of COVID-19 on the wellbeing of more than 2,000 families in the northern suburbs of Perth, measuring their perceived stress, financial hardship and family functioning during the pandemic.
We aimed to assess and identify any gaps in antimicrobial stewardship resources and activities for all hospitalised children in Australia pre- and post- the COVID-19 pandemic
Following widespread exposure to Omicron variants, SARS-CoV-2 has transitioned to endemic circulation. Populations now have diverse infection and vaccination histories, resulting in heterogeneous immune landscapes. Careful consideration of the value of ongoing vaccination is required through the post-Omicron phase of COVID-19 management to minimise disease burden.
Monitoring the number of COVID-19 patients in hospital beds was a critical component of Australia's real-time surveillance strategy for the disease. From 2021 to 2023, we produced short-term forecasts of bed occupancy to support public health decision-making.